Aldeyra Therapeutics
ALDX
111 hedge funds and large institutions have $172M invested in Aldeyra Therapeutics in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 39 reducing their positions, and 21 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
17% more capital invested
Capital invested by funds: $147M → $172M (+$25.2M)
3.65% more ownership
Funds ownership: 62.85% → 66.5% (+3.7%)
3% less funds holding
Funds holding: 115 → 111 (-4)
13% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 39
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
28% less call options, than puts
Call options by funds: $3.43M | Put options by funds: $4.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$8.73M |
| 2 |
TLP
Tri Locum Partners
New York
|
+$5.77M |
| 3 |
Goldman Sachs
New York
|
+$5.13M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$3.78M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.78M |
| 2 |
Millennium Management
New York
|
-$4.6M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$2.95M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2M |
| 5 |
Two Sigma Investments
New York
|
-$1.33M |
ALDX Hedge Fund Activity: Q1 2022 in Review
111 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2022, worth a combined $172M — up 17% from $147M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ALDX and 18 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 34 added.
The largest buyer was Citadel Advisors, adding an estimated $8.73M. The largest seller was State Street, cutting an estimated $8.78M.
- 111 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2022, down from 115 in Q4 2021.
- Funds reported $172M of Aldeyra Therapeutics stock for Q1 2022, up 17% quarter-over-quarter.
- 18 funds opened new Aldeyra Therapeutics positions in Q1 2022 and 21 closed out, a net change of -3 holders.
- The largest Aldeyra Therapeutics buyer in Q1 2022 was Citadel Advisors, an estimated $8.73M added.
- The largest Aldeyra Therapeutics seller in Q1 2022 was State Street, an estimated $8.78M sold.
Based on aggregated 13F filings for Q1 2022.